The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...
HALIFAX, NS / ACCESSWIRE / November 28, 2024 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2024. In December 2023, the Company ...
Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter MedMira Inc. has reported progress in expanding its market presence and securing regulatory approvals.
MedMira Inc. continues its North-American expansion plan HALIFAX, NS / ACCESSWIRE / October 3, 2024 / Today, MedMira Inc. (MedMira) (TSXV:MIR) today announced the appointment of Nicole Crenshaw as ...
Medmira (TSE:MIR) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended by top Wall Street analysts, ...
MedMira receives Health Canada approval for its Multiplo(R) Rapid (TP/HIV) Test for Syphilis and HIV
HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo ...
The Company's completed clinical trials showed a sensitivity of 100% for HIV-1 and HIV-2 MedMira's Reveal® G4 HIV-1/2 rapid antibody test achieved a flawless 100% specificity and was reactive in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback